Copyright
©The Author(s) 2020.
World J Hepatol. Sep 27, 2020; 12(9): 628-640
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.628
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.628
Table 4 mean (± SD) platelet counts in patients who had direct-acting antiviral therapy responses and failure (baseline, week 4, week 8, and week 12)
| SVR12 Achievement | Baseline PLT, | PLT at treatment week 4, mean (± SD) | PLT at treatment week 8, mean (± SD) | PLT at treatment week 12, mean (± SD) |
| Responders | 152.54 (± 55.880) | 172.33 (± 72.156) | 164.94 (± 53.580) | 169.42 (± 59.499) |
| Failures | 150.00 (± 35.157) | 153.00 (± 58.258) | 167.25 (± 57.058) | 160.67 (± 60.902) |
| P values | 0.9 | 0.5 | 0.9 | 0.7 |
- Citation: Ismail MS, Hassan M, Khaderi SA, Yousry WA, Kamal El-Din MM, Bahaa El-Din MM, El Sayed OA, Kaseb AO, Goss JA, Kanwal F, Jalal PK. Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. World J Hepatol 2020; 12(9): 628-640
- URL: https://www.wjgnet.com/1948-5182/full/v12/i9/628.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i9.628